The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Remdesivir for the Treatment of Covid-19 — Final Report
Open accessAbstract
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. RESULTS: A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%). CONCLUSIONS: Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hú, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,994
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,258 · cited 4×
“The trial site in South Korea received funding from the Seoul National University Hospital.”
InfluentialWang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,442
Sheahan, T. P., Sims, A. M., Leist, S. R., Schäfer, A., Won, J. J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D. M., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,757
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. M., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrć, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,575 · cited 3×
“There were 60 trial sites and 13 subsites in the United States (45 sites), Denmark (8), the United Kingdom (5), Greece (4), Germany (3), Korea (2), Mexico (2), Spain (2), Japan (1), and Singapore (1).”
Agostini, M. L., Andres, E. L., Sims, A. M., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,418
Spinner, C. D., Gottlieb, R., Criner, G. J., Arribas, J. R., Cattelan, A. M., Soriano, À., Ogbuagu, O. E., Malhotra, P., Mullane, K. M., Castagna, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.16349 · Cited by 1,234
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D. P., Cihlář, T., & Feldmann, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922083117 · Cited by 888
Cited by
Sorted by citations
Items 701–800 of 1,018
In vitro efficacy of Artemisia extracts against SARS-CoV-2
Nie, C., Trimpert, J., Moon, S., Haag, R., Gilmore, K. M., Kaufer, B. B., & Seeberger, P. H. (2021) · Virology Journal · doi:10.1186/s12985-021-01651-8 · Cited by 74
COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge
Furlan, A., Forner, G., Cipriani, L., Vian, E., Rigoli, R., Gherlinzoni, F., & Scotton, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.763412 · Cited by 74
Role of genomics in combating COVID-19 pandemic
Saravanan, K. A., Panigrahi, M., Kumar, H., Rajawat, D., Nayak, S. S., Bhushan, B., & Dutt, T. (2022) · Gene · doi:10.1016/j.gene.2022.146387 · Cited by 81
Post-acute COVID-19 syndrome and kidney diseases: what do we know?
Çöpür, S., Berkkan, M., Basile, C., Tuttle, K. R., & Kanbay, M. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01296-y · Cited by 76
Pitts, J., Li, J., Perry, J. K., Pont, V. D., Riola, N. C., Rodriguez, L., Lu, X., Kurhade, C., Xie, X., Camus, G., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00222-22 · Cited by 72
Jeong, J. H., Chokkakula, S., Min, S. C., Kim, B. K., Choi, W.-S., Oh, S., Yun, Y. S., Kang, D. H., Lee, O.-J., Kim, E., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105430 · Cited by 74
Differential privacy in deep learning: A literature survey
Pan, K., Ong, Y.-S., Gong, M., Li, H., Qin, A. K., & Gao, Y. (2024) · Neurocomputing · doi:10.1016/j.neucom.2024.127663 · Cited by 89
COVID-19 -Tuberculosis interactions: When dark forces collide
Udwadia, Z., Vora, A., Tripathi, A. K. R., Malu, K. N., Lange, C. G., & Raju, R. S. (2020) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2020.07.003 · Cited by 73
Vannucchi, A. M., Sordi, B., Morettini, A., Nozzoli, C., Poggesi, L., Pieralli, F., Bartoloni, A., Atanasio, A., Miselli, F., Paoli, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01018-y · Cited by 73
A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges
Hossen, M. S., Barek, M. A., Jahan, N., & Islam, M. S. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00485-9 · Cited by 75
The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm
Chau, A. S., Weber, A. G., Maria, N. I., Narain, S., Liu, A., Hajizadeh, N., Malhotra, P., Bloom, O., Marder, G. S., & Kaplan, B. M. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41526 · Cited by 75
Lyngbakken, M. N., Berdal, J., Eskesen, A. N., Kvale, D., Olsen, I. C., Rueegg, C. S., Rangberg, A., Jonassen, C. M., Omland, T., Røsjø, H. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19056-6 · Cited by 75
Dangerous Pathogens as a Potential Problem for Public Health
Janik, E., Ceremuga, M., Niemcewicz, M., & Bijak, M. (2020) · Medicina · doi:10.3390/medicina56110591 · Cited by 77
Remdesivir: From Ebola to COVID-19
Santoro, M. G., & Carafoli, E. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.11.043 · Cited by 75
In the interest of public safety: rapid response to the COVID-19 epidemic in Vietnam
Nguyễn, T. V., Tran, Q. D., Lan, P. T., Vu, L. N., Truong, D. T. T., Truong, H. C., Le, T. N., Khanh, L. V. D., Nguyen, T. V., Lương, Q. C., et al. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2020-004100 · Cited by 80
TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted Therapeutic Target
Bezemer, G. F. G., & Garssen, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.601685 · Cited by 73
Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases
Chen, Z., Cui, Q., Cooper, L. M., Zhang, P., Lee, H., Chen, Z., Wang, Y., Liu, X., Rong, L., & Du, R. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00564-x · Cited by 73
Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients
Zhong, H., Wang, Y., Shi, Z., Zhang, L., Ren, H., He, W., Zhang, Z., Zhu, A., Zhao, J., Xiao, F., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00257-2 · Cited by 73
Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence
Klassen, S. A., Senefeld, J. W., Senese, K. A., Johnson, P. W., Wiggins, C. C., Baker, S. E., van Helmond, N., Bruno, K. A., Pirofski, L., Shoham, S., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.684151 · Cited by 69
Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs
Schooley, R. T., Carlin, A. F., Beadle, J. R., Valiaeva, N., Zhang, X., Clark, A. E., McMillan, R. E., Leibel, S. L., McVicar, R. N., Xie, J., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01155-21 · Cited by 73
Manjunath, S. H., & Thimmulappa, R. K. (2021) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2021.09.009 · Cited by 76
Diabetes, Drug Treatment and Mortality in COVID-19: A Multinational Retrospective Cohort Study
Nyland, J. E., Raja-Khan, N. T., Bettermann, K., Haouzi, P. A., LESLIE, D. L., Kraschnewski, J. L., Parent, L. J., & Grigson, P. S. (2020) · Diabetes · doi:10.2337/db21-0385 · Cited by 74
A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice
Mao, T., Israelow, B., Lucas, C. G. D. O., Vogels, C. B. F., Gomez-Calvo, M. L., Fedorova, O., Breban, M. I., Menasché, B. L., Dong, H., Linehan, M. M., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20211818 · Cited by 70
Clinical presentation and management of COVID ‐19
Thevarajan, I., Buising, K. L., & Cowie, B. C. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50698 · Cited by 73
Potential role of interferons in treating COVID-19 patients
Abdolvahab, M. H., Moradi‐Kalbolandi, S., Zarei, M., Bose, D., Majidzadeh‐A, K., & Farahmand, L. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107171 · Cited by 71
Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science
Berlivet, L., & Löwy, I. (2020) · Medical Anthropology Quarterly · doi:10.1111/maq.12622 · Cited by 76
S2k-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19
Kluge, S., Janssens, U., Welte, T., Weber‐Carstens, S., Schälte, G., Spinner, C. D., Malin, J. J., Gastmeier, P., Länger, F. P., Wepler, M., et al. (2021) · Pneumologie · doi:10.1055/a-1334-1925 · Cited by 75
Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro
Du, R., Cooper, L. M., Chen, Z., Lee, H., Rong, L., & Cui, Q. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105075 · Cited by 75
Turmeric Root and Its Bioactive Ingredient Curcumin Effectively Neutralize SARS-CoV-2 In Vitro
Bormann, M., Alt, M., Schipper, L., van de Sand, L., Le‐Trilling, V. T. K., Rink, L., Heinen, N., Madel, R. J., Otte, M., Wuensch, K., et al. (2021) · Viruses · doi:10.3390/v13101914 · Cited by 79
Phototherapy and optical waveguides for the treatment of infection
Wang, D., Kuzma, M. L., Tan, X., He, T., Dong, C., Liu, Z., & Yang, J. Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114036 · Cited by 73
Communicating Science in the Time of a Pandemic
Saitz, R., & Schwitzer, G. (2020) · JAMA · doi:10.1001/jama.2020.12535 · Cited by 71
Aktaş, G. (2020) · Experimental Biomedical Research · doi:10.30714/j-ebr.2020463629 · Cited by 72
A Systematic Review of Systematic Reviews on the COVID-19 Pandemic
Hatmi, Z. N. (2021) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-021-00749-y · Cited by 69
Johnston, C., Brown, E. R., Stewart, J. C., Karita, H. C. S., KISSINGER, P. J., Dwyer, J., Hosek, S., Oyedele, T., Paasche‐Orlow, M. K., Paolino, K. M., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100773 · Cited by 71
Coronavirus Disease 2019 in Children
Borrelli, M., Corcione, A., Castellano, F., Nastro, F. F., & Santamaria, F. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.668484 · Cited by 75
Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence
Hsieh, K., Wang, Y., Chen, L., Zhao, Z., Savitz, S. I., Jiang, X., Tang, J. P., & Kim, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-02353-5 · Cited by 71
Therapeutics for COVID-19 and post COVID-19 complications: An update
Basu, D., Chavda, V. P., & Mehta, A. A. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100086 · Cited by 72
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia
O’Halloran, J. A., Ko, E. R., Anstrom, K. J., Kedar, E., McCarthy, M. W., Panettieri, R. A., Maillo, M., Nunez, P. S., Lachiewicz, A. M., Gonzalez, C., et al. (2023) · JAMA · doi:10.1001/jama.2023.11043 · Cited by 73
SARS‐CoV‐2 and HIV coinfection: clinical experience from Rhode Island, United States
Byrd, K. M., Beckwith, C. G., Garland, J. M., Johnson, J. E., Aung, S., Cu‐Uvin, S., Farmakiotis, D., Flanigan, T., Gillani, F. S., Gil, R. M., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25573 · Cited by 70
COVID‐19‐related disease severity in pregnancy
Thompson, J. L., Nguyen, L. M., Noble, K. N., & Aronoff, D. M. (2020) · American Journal of Reproductive Immunology · doi:10.1111/aji.13339 · Cited by 68
Immunity and inflammatory biomarkers in COVID‐19: A systematic review
Iwamura, A. P. D., da Silva, M. R. T., Hümmelgen, A. L., Pereira, P. V. S., Falcai, Â., Grumach, A. S., Goudouris, E., Condino‐Neto, A., & Prando, C. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2199 · Cited by 71
Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study
Jorge, A. M., D’Silva, K. M., Cohen, A., Wallace, Z. S., McCormick, N., Zhang, Y., & Choi, H. K. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30422-7 · Cited by 70
The find of COVID-19 vaccine: Challenges and opportunities
ElBagoury, M., Tolba, M. M., Nasser, H. A., Jabbar, A., Elagouz, A. M., Aktham, Y., & Hutchinson, A. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.12.025 · Cited by 71
Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease
Deshmukh, M. G., Ippolito, J. A., Zhang, C., Stone, E. A., Reilly, R. A., Miller, S. J., Jorgensen, W. L., & Anderson, K. S. (2021) · Structure · doi:10.1016/j.str.2021.06.002 · Cited by 70
Time-Dependent COVID-19 Mortality in Patients With Cancer
OnCovid study group, Pinato, D. J., Patel, M., Scotti, L., Colomba, É., Dolly, S. O., Loizidou, A., Chester, J. D., Mukherjee, U., Zambelli, A., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.6199 · Cited by 72
Recent review of COVID-19 management: diagnosis, treatment and vaccination
Chavda, V. P., Vuppu, S., Mishra, T., Kamaraj, S., Patel, A., Sharma, N., & Chen, Z. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00425-5 · Cited by 73
“According to existing evidence, patients on treatment have an average hospitalization time of 15 days, whereas patients on remdesivir have an average hospitalization time of 11 days[55].”
MethodFord, E. S., Simmons, W. R., Karmarkar, E. N., Yoke, L. H., Braimah, A. B., Orozco, J. J., Ghiuzeli, C. M., Barnhill, S., Sack, C. L., Benditt, J. O., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac868 · Cited by 71
Endpoints for randomized controlled clinical trials for COVID-19 treatments
Dodd, L. E., Follmann, D. A., Wang, J., König, F., Korn, L. L., Schoergenhofer, C., Proschan, M. A., Hunsberger, S., Bonnett, T., Makowski, M., et al. (2020) · Clinical Trials · doi:10.1177/1740774520939938 · Cited by 65
Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome
Matthay, M. A., & Wick, K. D. (2020) · Journal of Clinical Investigation · doi:10.1172/jci143331 · Cited by 68
Antiviral therapies: advances and perspectives
Gonçalves, B. C., Barboza, M. G. L., Olak, A. P. S., Terezo, N. B., Nishi, L., Watanabe, M. A. E., Marinello, P. C., Rechenchoski, D. Z., Rocha, S. P. D., & Galhardi, L. C. F. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12609 · Cited by 70
Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2
Dong, J., Huang, B. C. B., Wang, B., Titong, A., Kankanamalage, S. G., Jia, Z., Wright, M., Parthasarathy, P., & Liu, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-74761-y · Cited by 67
Blockage of interleukin-1β with canakinumab in patients with Covid-19
Landi, L. M., Ravaglia, C., Russo, E., Cataleta, P., Fusari, M., Boschi, A., Giannarelli, D., Facondini, F., Valentini, I., Panzini, I., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78492-y · Cited by 70
Gérard, A. O., Laurain, A., Fresse, A., Parassol, N., Muzzone, M., Rocher, F., Esnault, V. L. M., & Drici, M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2145 · Cited by 69
Baker, J. D., Uhrich, R. L., Kraemer, G. C., Love, J. E., & Kraemer, B. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245962 · Cited by 69
Cremer, P. C., Abbate, A., Hudock, K. M., McWilliams, C. S., Mehta, J. P., Chang, S. Y., Sheng, C. C., Tassell, B. W. V., Bonaventura, A., Vecchié, A., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00070-9 · Cited by 68
Yates, T. E., Zaccardi, F., Islam, N., Razieh, C., Gillies, C., Lawson, C. A., Chudasama, Y., Rowlands, A. V., Davies, M. J., Docherty, A. B., et al. (2021) · Obesity · doi:10.1002/oby.23178 · Cited by 65
Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening
Ebisudani, T., Sugimoto, S., Haga, K., Mitsuishi, A., Takai‐Todaka, R., Fujii, M., Toshimitsu, K., Hamamoto, J., Sugihara, K., Hishida, T., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109218 · Cited by 69
Gupte, V., Hegde, R., Sawant, S., Kalathingal, K., Jadhav, S., Malabade, R., & Gogtay, J. A. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-021-07004-8 · Cited by 69
Burton, M. J., Clarkson, J., Goulão, B., Glenny, A., McBain, A. J., Schilder, A. G., Webster, K. E., & Worthington, H. V. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013627.pub2 · Cited by 69
Metabolic Efficacy of Phosphate Prodrugs and the Remdesivir Paradigm
Wiemer, A. J. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00076 · Cited by 68
Mann, J. K., & Ndung’u, T. (2020) · Future Virology · doi:10.2217/fvl-2020-0170 · Cited by 65
Amengual, O., & Atsumi, T. (2020) · Rheumatology International · doi:10.1007/s00296-020-04744-9 · Cited by 68
An update review of emerging small-molecule therapeutic options for COVID-19
Tian, D., Liu, Y., Liang, C., Xin, L., Xie, X., Zhang, D., Wan, M., Li, H., Fu, X., Liu, H., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111313 · Cited by 68
SARS-CoV-2 vaccines for cancer patients: a call to action
Corti, C., Crimini, E., Tarantino, P., Pravettoni, G., Eggermont, A. M. M., Delaloge, S., & Curigliano, G. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.046 · Cited by 68
Xie, J., & Wang, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.028 · Cited by 69
Elucidating the Neuropathologic Mechanisms of SARS-CoV-2 Infection
Pacheco‐Herrero, M., Soto-Rojas, L. O., Harrington, C. R., Flores-Martinez, Y. M., Villegas-Rojas, M. M., León-Aguilar, A. M., Martínez-Gómez, P. A., Campa-Córdoba, B. B., Apátiga-Pérez, R., Corniel-Taveras, C. N., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.660087 · Cited by 71
Pulmonary Edema in COVID-19 Patients: Mechanisms and Treatment Potential
Cui, X., Chen, W., Zhou, H., Gong, Y., Zhu, B., Lv, X., Guo, H., Duan, J., Zhou, J., Marcon, E., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.664349 · Cited by 70
Puskarich, M. A., Cummins, N. W., Ingraham, N. E., Wacker, D. A., Reilkoff, R. A., Driver, B. E., Biros, M. H., Bellolio, F., Chipman, J. G., Nelson, A., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100957 · Cited by 68
Milligan, J. C., Zeisner, T. U., Papageorgiou, G., Joshi, D., Soudy, C., Ulferts, R., Wu, M., Lim, C. T., Tan, K. W., Weissmann, F., et al. (2021) · Biochemical Journal · doi:10.1042/bcj20210197 · Cited by 66
Liu, A., Han, J., Nakano, A., Konno, H., Moriwaki, H., Abe, H., Izawa, K., & Soloshonok, V. A. (2021) · Chirality · doi:10.1002/chir.23376 · Cited by 69
Temesgen, Z., Burger, C. D., Baker, J., Polk, C. M., Libertin, C. R., Kelley, C. F., Marconi, V. C., Orenstein, R., Catterson, V. M., Aronstein, W. S., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00494-x · Cited by 70
Chokkalingam, A. P., Hayden, J., Goldman, J. D., Li, H., Asubonteng, J. O., Mozaffari, E., Bush, C., Wang, J. R., Kong, A. M., Osinusi, A. O., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.44505 · Cited by 68
Development of a General Organophosphorus Radical Trap: Deoxyphosphonylation of Alcohols
Bissonnette, N. B., Bisballe, N., Tran, A. V., Rossi‐Ashton, J. A., & MacMillan, D. W. C. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c00557 · Cited by 66
Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled
Goletti, D., & Cantini, F. (2021) · New England Journal of Medicine · doi:10.1056/nejme2034982 · Cited by 68
Wu, B., Luo, M., Wu, F., He, Z., Li, Y., & Xu, T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.692828 · Cited by 63
“For this reason, clinical studies excluded renal insufficiency recipients with an estimated glomerular filtration rate (eGFR) of <30 ml/min (Beigel et al., 2020; Wang et al., 2020) or eGFR <50 ml/min (Joyner et al.”
BackgroundCharan, J., Kaur, R. J., Bhardwaj, P., Haque, M., Sharma, P., Misra, S., & Godman, B. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1856655 · Cited by 67
Byléhn, F., Menéndez, C. A., Pérez-Lemus, G. R., Alvarado, W., & Pablo, J. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01242 · Cited by 70
Generation and Characterization of Recombinant SARS-CoV-2 Expressing Reporter Genes
Chiem, K., Vasquez, D. M., Park, J., Platt, R. N., Anderson, T., Walter, M. R., Kobie, J. J., Ye, C., & Martínez‐Sobrido, L. (2021) · Journal of Virology · doi:10.1128/jvi.02209-20 · Cited by 67
Reactive arthritis after COVID-19
Hønge, B. L., Hermansen, M. F., & Storgaard, M. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-241375 · Cited by 70
Synergistic Inhibition of SARS-CoV‑2 Replication Using Disulfiram/Ebselen and Remdesivir
Chen, T., Fei, C., Chen, Y., Sargsyan, K., Chang, C., Yuan, H. S., & Lim, C. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00022 · Cited by 67
Duration of post–COVID-19 symptoms is associated with sustained SARS-CoV-2–specific immune responses
Files, J. K., Sarkar, S., Fram, T., Boppana, S., Sterrett, S., Qin, K., Bansal, A., Long, D. M., Sabbaj, S., Kobie, J. J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151544 · Cited by 69
Grau, S., Hernández, S., Echeverría-Esnal, D., Almendral, A., Ferrer, R., Cáceres, E. L., Horcajada, J. P., & (VINCat-PROA), O. B. O. T. C. I. C. A. S. P. (2021) · Antibiotics · doi:10.3390/antibiotics10080943 · Cited by 67
Ambike, S. S., Cheng, C., Feuerherd, M., Velkov, S., Baldassi, D., Afridi, S. Q., Porras-Gonzalez, D., Wei, X. C., Hagen, P., Kneidinger, N., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1248 · Cited by 73
Marrone, A., Nevola, R., Sellitto, A., Cozzolino, D., Romano, C. P., Cuomo, G., Aprea, C., Schwartzbaum, M. X. P., Ricozzi, C., Imbriani, S., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac014 · Cited by 67
Patients with CLL have a lower risk of death from COVID-19 in the Omicron era
Niemann, C. U., da Cunha‐Bang, C., Helleberg, M., Ostrowski, S. R., & Brieghel, C. (2022) · Blood · doi:10.1182/blood.2022016147 · Cited by 66
“Remdesivir was widely used for hematological patients regardless of disease severity since approval mid-2020.(13,14) Sotrovimab retained its neutralizing activities against the Omicron BA.”
MethodWagoner, J., Herring, S., Hsiang, T.-Y., Ianevski, A., Biering, S. B., Xu, S. B., Hoffmann, M., Pöhlmann, S., Gale, M., Aittokallio, T. A., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.03331-22 · Cited by 72
Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options
Pelle, M. C., Zaffina, I., Lucà, S., Forte, V., Trapanese, V., Melina, M., Giofrè, F., & Arturi, F. (2022) · Life · doi:10.3390/life12101605 · Cited by 72
The RECOVERY Collaborative Group, Horby, P., Estcourt, L. J., Peto, L., Emberson, J., Staplin, N., Spata, E., Pessoa-Amorim, G., Campbell, M. R., Roddick, A., et al. (2021) · medRxiv · doi:10.1101/2021.03.09.21252736 · Cited by 69
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
White, J. M., Schiffer, J. T., Bender Ignacio, R. A., Xu, S., Kainov, D., Ianevski, A., Aittokallio, T., Frieman, M., Olinger, G. G., & Polyak, S. J. (2021) · mBio · doi:10.1128/mbio.03347-21 · Cited by 64
Haque, M., Islam, S., Iqbal, S., Urmi, U. L., Kamal, Z. M., Rahman, A., Kamal, M., Haque, M., Jahan, I., Islam, M. Z., et al. (2020) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v19i0.48106 · Cited by 72
Joseph, N. P., Reid, N., Som, A., Li, M., Hyle, E. P., Dugdale, C. M., Lang, M., Betancourt, J. R., Deng, F. M., Mendoza, D. P., et al. (2020) · Radiology · doi:10.1148/radiol.2020202602 · Cited by 67
A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY
Lutchmansingh, D. D., Knauert, M. P., Antin-Ozerkis, D. E., Chupp, G. L., Cohn, L. E., Cruz, C. S. D., Ferrante, L. E., Herzog, E. L., Koff, J. L., Rochester, C. L., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.10.067 · Cited by 66
Sandhu, T., Tieng, A. T., Chilimuri, S. S., & Franchin, G. (2020) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2020/8865954 · Cited by 66
Coronavirus disease 2019 vaccines in pregnancy
Craig, A. M., Hughes, B. L., & Swamy, G. K. (2020) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2020.100295 · Cited by 66
Richardson, E. T., Malik, M. M., Darity, W. A. J., Mullen, A., Morse, M. E., Malik, M., Maybank, A., Bassett, M. T., Farmer, P. E., Worden, L., et al. (2021) · Social Science & Medicine · doi:10.1016/j.socscimed.2021.113741 · Cited by 74
Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19
Mahajan, L. S., Singh, A. P., & Gifty (2021) · Indian Journal of Anaesthesia · doi:10.4103/ija.ija_149_21 · Cited by 66
the COVID-ICU investigators, Dres, M., Hajage, D., Lebbah, S., Kimmoun, A., Pham, T. O., Beduneau, G., Combes, A., Mercat, A., Guidet, B., et al. (2020) · Annals of Intensive Care · doi:10.1186/s13613-021-00861-1 · Cited by 67
Canal, B., Fujisawa, R., McClure, A. W., Deegan, T. D., Wu, M., Ulferts, R., Weissmann, F., Drury, L. S., Bertolin, A. P., Zeng, J., et al. (2021) · Biochemical Journal · doi:10.1042/bcj20210199 · Cited by 65
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Roeker, L. E., Eyre, T. A., Thompson, M. C., Lamanna, N., Coltoff, A. R., Davids, M. S., Baker, P. O., Leslie, L. A., Rogers, K. A., Allan, J. N., et al. (2021) · Blood · doi:10.1182/blood.2021011841 · Cited by 66
Angamo, M. T., Mohammed, M. A., & Peterson, G. M. (2021) · Infection · doi:10.1007/s15010-021-01671-0 · Cited by 66
Metadata
- Authors
- Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., Touloumi, G., Lye, D. C., Ohmagari, N., Oh, M.-D., Ruiz-Palacios, G. M., Benfield, T., Fätkenheuer, G., Kortepeter, M. G., Atmar, R. L., Creech, C. B., Lundgren, J., Babiker, A. G., Pett, S., Neaton, J. D., Burgess, T. H., Bonnett, T., Green, M., Makowski, M., Osinusi, A., Nayak, S., & Lane, H. C.
- Affiliations
- National Institutes of Health (US)
- From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) — all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical...
- Corresponding author
- Beigel, John H.
- ORCID
- Beigel, John H.
- Dodd, Lori E.
- Mehta, Aneesh K.
- Zingman, Barry S.
- Kalil, Andre C.
- Hohmann, Elizabeth
- Chu, Helen Y.
- Luetkemeyer, Annie
- Kline, Susan
- Finberg, Robert W.
- Dierberg, Kerry
- Tapson, Victor
- Patterson, Thomas F.
- Paredes, Roger
- Short, William R.
- Touloumi, Giota
- Lye, David Chien
- Ohmagari, Norio
- Oh, Myoung-don
- Ruiz-Palacios, Guillermo M.
- Benfield, Thomas
- Fätkenheuer, Gerd
- Atmar, Robert L.
- Creech, C. Buddy
- Lundgren, Jens
- Babiker, Abdel G.
- Pett, Sarah
- Neaton, James D.
- Burgess, Timothy H.
- Bonnett, Tyler
- Makowski, Mat
- Nayak, Seema
- Lane, H. Clifford
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-11-05
- Volume
- 383
- Issue
- 19
- Pages
- 1813-1826
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7262788
- OpenAlex
- W3027630905
- Cited by
- 7,267
- References
- 22
- Citations by year
- 2026: 146 · 2025: 324 · 2024: 518 · 2023: 901 · 2022: 1447 · 2021: 2475 · 2020: 1451
- FWCI
- 206.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Figshare (submittedVersion, cc-by)
- Sussex Research Online (University of Sussex) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- eScholarship@McGill (McGill) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Cancer Institute (HHSN261200800001E, HHSN261201500003I)
- National Institute of Allergy and Infectious Diseases (UM1AI148450, UM1AI148452, UM1AI148573, UM1AI148575, UM1AI148576, UM1AI148684, UM1AI148685, UM1AI148689)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
- Keywords
- remdesivir, COVID-19 pandemic, SARS-CoV-2, antiviral therapy, hospitalized patients, lower respiratory tract infection, time to recovery, mortality, serious adverse events, clinical improvement, treatment efficacy, SARS-CoV-2 RNA load, viral load reduction, disease severity, prognostic factors, prognostic score
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Adenosine Monophosphate, Adult, Aged, Alanine, Antiviral Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Oxygen Inhalation Therapy, Pneumonia, Viral, Respiration, Artificial, Time Factors, Extracorporeal Membrane Oxygenation, Coronavirus Infections, Kaplan-Meier Estimate, Young Adult, Pandemics, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
